Yoon, Hong In <br/><br/>
Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.  [electronic resource] 

 -  Journal of cancer research and clinical oncology  Mar 2014 
 - 399-409 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-1335 
<br/><br/><label>Standard No.: </label>10.1007/s00432-013-1578-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Carcinoembryonic Antigen--blood<br/>Chemoradiotherapy, Adjuvant--adverse effects<br/>Enzyme-Linked Immunosorbent Assay<br/>ErbB Receptors--blood<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>Neoplasm Staging<br/>Predictive Value of Tests<br/>Prospective Studies<br/>Receptors, Urokinase Plasminogen Activator--blood<br/>Rectal Neoplasms--blood<br/>Tissue Inhibitor of Metalloproteinase-1--blood<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--blood